An Update on the International Society of Pharmacovigilance China Chapter Yalu WenTianyi YangXiaohui Yang From the ISoP 25 June 2022 Pages: 699 - 702
Incidence, Pathogenesis, and Management of Proton Pump Inhibitor-Induced Nephrotoxicity Xiao WeiJun YuYonggui Wu Review Article 01 June 2022 Pages: 703 - 712
Prevalence of Use of Traditional, Complementary and Alternative Medicine by the General Population: A Systematic Review of National Studies Published from 2010 to 2019 E Lyn LeeNoni RichardsJoanne Barnes Systematic Review Open access 05 July 2022 Pages: 713 - 735
Safety-Related Drug Withdrawals in China Between 1999 and 2021: A Systematic Investigation and Analysis Yanrong LiYang JiangYue Yang Original Research Article Open access 12 July 2022 Pages: 737 - 745
Collection of Data on Adverse Events Related to Medicinal Products: A Survey Among Registries in the ENCePP Resources Database Kelly PlueschkeCarla JonkerXavier Kurz Original Research Article Open access 21 June 2022 Pages: 747 - 754
Quantitative Prediction of Adverse Event Probability Due to Pharmacokinetic Interactions Michel TodThomas RodierMarine Auffret Original Research Article 23 June 2022 Pages: 755 - 764
Signaling COVID-19 Vaccine Adverse Events Rave HarpazWilliam DuMouchelMagnus Lerch Original Research Article Open access 23 June 2022 Pages: 765 - 780
Incidence of Acute Renal Failure in Patients Using Levetiracetam Versus Other Antiseizure Medications: A Voluntary Post-Authorization Safety Study Raphaelle Beau-LejdstromLai San HongNadia Foskett Original Research Article 28 June 2022 Pages: 781 - 790
Hip Fracture Risk After Treatment with Tramadol or Codeine: An Observational Study Erica A. VossSaberi Rana AliDaniel Fife Original Research Article Open access 09 July 2022 Pages: 791 - 807
Comment on: "Drug–Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data" Yoshihiro Noguchi Letter to the Editor 17 June 2022 Pages: 809 - 811
Authors’ Reply to Noguchi’s comment on: “Drug-Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data.” John-Michael GambleWajd Alkabbani Letter to the Editor 17 June 2022 Pages: 813 - 814